PSNL News and Press, Personalis Inc. From 08/01/19

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the latest expansion of its universal cancer immunogenomics platform, ImmunoID NeXT , incorporating several additional features that are pivotal to the understanding of tumor and immune cell interactio...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its second quarter 2019 financial results after the market closes on Tuesday, August 13, 2019. In conjunction with the release, the Company will host a conference call and webcast that d...

Point Roberts, WA and Delta, BC - July 19, 2019 (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week's additions to its global stock directories in biotech, tech and defense. This week's new additions are all recent Nasdaq IPO...

Akero Therapeutics (NASDAQ: AKRO ) initiated with Buy rating and $28 (41% upside) price target at Jefferies. Shares down a fraction premarket. More news on: Akero Therapeutics, Inc., Atreca, Inc., Personalis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you ca...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...

Sourced by Personalis: Personalis (PSNL) has the potential for becoming one of the key players in the growing immunotherapy market with an established and budding ability to provide the analytical molecular data for individual patient's cancer and immune response. In my opinion, the current ...